Home
>
US Stocks
>
ANNOVIS BIO

ANNOVIS BIO (ANVS)

$13.39

+0.34

(+2.61%)▲

Market is closed - opens 7 PM, 30 May 2023

Insights on ANNOVIS BIO

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 4.6%

Performance

  • $13.12
    $13.49
    $13.39
    downward going graph

    2.02%

    Downside

    Day's Volatility :2.71%

    Upside

    0.71%

    downward going graph
  • $8.98
    $23.91
    $13.39
    downward going graph

    32.94%

    Downside

    52 Weeks Volatility :62.44%

    Upside

    44.0%

    downward going graph

Returns

PeriodANNOVIS BIOSector (Health Care)Index (Russel 2000)
3 Months
-21.74%
0.3%
-6.7%
6 Months
4.12%
-6.1%
-3.7%
1 Year
45.86%
-4.8%
-6.3%
3 Years
201.58%
23.8%
26.9%

Highlights

Market Capitalization
117.5M
Book Value
$2.45
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.46
Wall Street Target Price
46.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-54.88%
Return On Equity TTM
-95.96%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-3.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.59
EPS Estimate Next Year
-3.5
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for ANNOVIS BIO(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 243.54%

Current $13.39
Target $46.00

Technicals Summary

Sell

Neutral

Buy

ANNOVIS BIO is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
ANNOVIS BIO
ANNOVIS BIO
-9.83%
4.12%
45.86%
201.58%
39.62%
Moderna, Inc.
Moderna, Inc.
-5.37%
-27.09%
-13.14%
105.27%
578.71%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.19%
-1.57%
8.99%
18.23%
144.36%
Seagen, Inc.
Seagen, Inc.
-2.85%
64.85%
42.61%
23.08%
248.38%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.35%
4.32%
22.83%
14.6%
112.57%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
ANNOVIS BIO
ANNOVIS BIO
NA
NA
NA
-4.59
-0.96
-0.55
0.0
2.45
Moderna, Inc.
Moderna, Inc.
11.28
11.28
0.0
-1.96
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.02
20.02
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.02
27.02
0.41
14.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
ANNOVIS BIO
ANNOVIS BIO
Buy
$117.5M
39.62%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.2B
578.71%
11.28
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
144.36%
20.02
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
248.38%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.7B
112.57%
27.02
35.4%

Institutional Holdings

  • Vanguard Group Inc

    2.69%

  • BlackRock Inc

    1.15%

  • Geode Capital Management, LLC

    0.48%

  • Merit Financial Group, LLC

    0.48%

  • Wescott Financial Advisory Group, LLC

    0.46%

  • Bank of New York Mellon Corp

    0.38%

Corporate Announcements

  • ANNOVIS BIO Earnings

    ANNOVIS BIO’s price-to-earnings ratio stands at None

    Read More

Company Information

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). The Comapny's believes that it is the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The Company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. The Company has two ongoing Phase 2a studies: one in AD patients and one in both AD and PD patients.

Organization
ANNOVIS BIO
Employees
5
CEO
Dr. Maria L. Maccecchini Ph.D.
Industry
Electronic Equipment/Instruments

Discover More

FAQs